Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier.

64 out-patients suffering from recurrent UTI were treated under double-blind conditions with one capsule daily of either the biological response modifier OM-8930 or the placebo for 3 months, followed by a 3-month observation period. Dysuria, bacteriuria, leucocyturia and antibiotic or chemotherapeutic consumption showed a significant reduction under OM-8930 in comparison with the placebo. As to the tolerance, a single case of allergic exanthema on the neck was observed in the OM-8930 group. Both the curative efficacy in the acute crisis and the consolidative efficacy in preventing further recurrences showed a highly significant superior effect of OM-8930 with respect to the placebo.

RCT Entities:   Population Interventions Outcomes